A biotechnology company and a non-profit are joining forces to bring a safe source of psilocybin to patients wanting to receive psychedelics-assisted therapy.
On Monday, Vancouver-based firm Havn Life Sciences Inc.(CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) announced a partnership with the Victoria-based non-profit TheraPsil.
Under the partnership, TheraPsil will support healthcare professionals requesting psilocybin via the Special Access Program (SAP) and get the psychedelic from Havn and other psychedelics dealers enrolled in the non-profit’s “‘Project Solace”.
Share this post
